Verastem Inc (VSTM)

$4.29 +0.14 (3.37%)
Market Cap 228.04M
Revenue (ttm) 10.00M
Net Income (ttm) -130.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,306.40%
Debt to Equity Ratio -2.20
Volume 2,720,500
Avg Vol 2,248,710
Day's Range N/A - N/A
Shares Out 54.95M
Stochastic %K 8%
Beta 0.85
Analysts Strong Sell
Price Target $15.25

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
SagehenNed
SagehenNed Jul. 1 at 7:09 PM
$VSTM right on cue, the 3pm selling begins. Lucky if we end up green.
1 · Reply
Damian23
Damian23 Jul. 1 at 6:28 PM
$VSTM Trump’s “Big, Beautiful Bill” has officially passed the U.S. Senate with a narrow 51-50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill had already passed the House, and Trump is expected to sign it into law by July 4. How the Bill Will Affect Bio Stocks 1. Medicaid Cuts and Healthcare Spending The bill includes $1.2 trillion in cuts to Medicaid and other federal aid programs over the next decade. These cuts are expected to increase the number of uninsured Americans and put financial pressure on hospitals, especially those serving low-income populations. Biotech and pharmaceutical companies could see reduced demand for their products and therapies, particularly those heavily reliant on Medicaid reimbursements. This is already causing investor uncertainty and reduced funding for biotech firms.
1 · Reply
PencilNeckGeek
PencilNeckGeek Jul. 1 at 6:25 PM
$VSTM will be pleasantly surprised if it holds gains today's but it's unlikely unfortunately
1 · Reply
Marketismanipulated2
Marketismanipulated2 Jul. 1 at 5:40 PM
$VSTM who thinks the thieves will run it right back down? 👋
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 1 at 5:18 PM
$VSTM is down roughly 50% since its combo therapy was approved 5/8/25 for a rare ovarian cancer VSTM's combo is priced @ $630K per year. Assuming an 80% gross to net this is ~$500K/patient/year. 2 to 5% of the ~20,000 new ovarian cases per year in the US would be indicated for VSTM's therapy. Existing prevalence is est @ 6,000-8,000 patients in the US (80,000 globally). Attached is a table that shows VSTM trades for 0.06X 10-year analyst consensus revenue estimates. The table notes 6 peers acquired at 0.33 to 0.41X 10-year revenue estimates (though VSTM's gross margin profile is not known yet). If consensus estimates are credible & if VSTM's combo is worth a peer multiple (2 HUGE IFS) then VSTM's risk/reward profile appears compelling. VSTM may also continue as an independent. 95-98% of new cancer drugs in Phase 1 are never approved. Since 1/1/2013 only $SNDX has 2 cancer approvals (w $INCY) with meaningful TAMs. Fingers crossed for M&A. This is not investment advice. $XBI
0 · Reply
Gainermaxim
Gainermaxim Jul. 1 at 5:09 PM
$VSTM she is coming back!
0 · Reply
Marketismanipulated2
Marketismanipulated2 Jul. 1 at 4:54 PM
$VSTM i bought 70k dollars yesterday at $4.04 and sold it all at $4.17 yesterday trying to capitalize on their crimes, guess I still did, wish i kept it all now.
0 · Reply
Adorno99
Adorno99 Jul. 1 at 4:41 PM
$VSTM safe to dip your toes? Should have bought when it was 4.04 or so
1 · Reply
bluermefox
bluermefox Jul. 1 at 4:15 PM
$VSTM safe to dip our toes?
0 · Reply
PencilNeckGeek
PencilNeckGeek Jul. 1 at 4:04 PM
$VSTM Glad to see it looking better today. Would be nice if the worst is over, but not gonna get my hopes up just yet
0 · Reply
Latest News on VSTM
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 30, 2025, 4:02 PM EDT - 1 day ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 26, 2025, 11:16 AM EDT - 5 days ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 24, 2025, 4:02 PM EDT - 7 days ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Jun 2, 2025, 9:40 AM EDT - 4 weeks ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 4 weeks ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22, 2025, 5:01 PM EDT - 5 weeks ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20, 2025, 8:30 AM EDT - 6 weeks ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025, 4:34 PM EDT - 7 weeks ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 1:17 PM EDT - 7 weeks ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 7 weeks ago

U.S. FDA approves Verastem's cancer therapy

Verastem Oncology to Present at Upcoming Investor Conferences

May 1, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 2 months ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 23, 2025, 4:05 PM EDT - 2 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Apr 10, 2025, 2:35 PM EDT - 2 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 7, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 25, 2025, 4:35 PM EDT - 3 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Mar 20, 2025, 4:01 PM EDT - 3 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 20, 2025, 4:05 PM EST - 4 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 5 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 23, 2025, 7:30 AM EST - 5 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 15, 2025, 7:30 AM EST - 5 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 14, 2025, 7:30 AM EST - 6 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 13, 2025, 7:30 AM EST - 6 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem: Planning The PDUFA Run-Up

Jan 3, 2025, 11:56 AM EST - 6 months ago

Verastem: Planning The PDUFA Run-Up

Verastem: BLA Acceptance Puts Key Goals In Sight

Jan 2, 2025, 11:39 AM EST - 6 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 31, 2024, 10:59 AM EST - 6 months ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 30, 2024, 4:30 PM EST - 6 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 18, 2024, 7:30 AM EST - 6 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem: Preparing For Upcoming Catalysts

Nov 27, 2024, 1:28 PM EST - 7 months ago

Verastem: Preparing For Upcoming Catalysts

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 26, 2024, 7:00 AM EST - 7 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 6, 2024, 4:05 PM EST - 8 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 4:01 PM EDT - 8 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 31, 2024, 7:30 AM EDT - 8 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 17, 2024, 1:00 AM EDT - 9 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 9 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 10 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 10, 2024, 7:30 AM EDT - 10 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 5, 2024, 11:21 PM EDT - 10 months ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Sep 3, 2024, 7:30 AM EDT - 10 months ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Aug 8, 2024, 4:05 PM EDT - 11 months ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 11:20 PM EDT - 1 year ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Jul 12, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Verastem, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 10, 2024, 2:48 PM EDT - 1 year ago

Verastem, Inc. Investors: Company Investigated by the Portnoy Law Firm

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

Jul 1, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

SagehenNed
SagehenNed Jul. 1 at 7:09 PM
$VSTM right on cue, the 3pm selling begins. Lucky if we end up green.
1 · Reply
Damian23
Damian23 Jul. 1 at 6:28 PM
$VSTM Trump’s “Big, Beautiful Bill” has officially passed the U.S. Senate with a narrow 51-50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill had already passed the House, and Trump is expected to sign it into law by July 4. How the Bill Will Affect Bio Stocks 1. Medicaid Cuts and Healthcare Spending The bill includes $1.2 trillion in cuts to Medicaid and other federal aid programs over the next decade. These cuts are expected to increase the number of uninsured Americans and put financial pressure on hospitals, especially those serving low-income populations. Biotech and pharmaceutical companies could see reduced demand for their products and therapies, particularly those heavily reliant on Medicaid reimbursements. This is already causing investor uncertainty and reduced funding for biotech firms.
1 · Reply
PencilNeckGeek
PencilNeckGeek Jul. 1 at 6:25 PM
$VSTM will be pleasantly surprised if it holds gains today's but it's unlikely unfortunately
1 · Reply
Marketismanipulated2
Marketismanipulated2 Jul. 1 at 5:40 PM
$VSTM who thinks the thieves will run it right back down? 👋
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 1 at 5:18 PM
$VSTM is down roughly 50% since its combo therapy was approved 5/8/25 for a rare ovarian cancer VSTM's combo is priced @ $630K per year. Assuming an 80% gross to net this is ~$500K/patient/year. 2 to 5% of the ~20,000 new ovarian cases per year in the US would be indicated for VSTM's therapy. Existing prevalence is est @ 6,000-8,000 patients in the US (80,000 globally). Attached is a table that shows VSTM trades for 0.06X 10-year analyst consensus revenue estimates. The table notes 6 peers acquired at 0.33 to 0.41X 10-year revenue estimates (though VSTM's gross margin profile is not known yet). If consensus estimates are credible & if VSTM's combo is worth a peer multiple (2 HUGE IFS) then VSTM's risk/reward profile appears compelling. VSTM may also continue as an independent. 95-98% of new cancer drugs in Phase 1 are never approved. Since 1/1/2013 only $SNDX has 2 cancer approvals (w $INCY) with meaningful TAMs. Fingers crossed for M&A. This is not investment advice. $XBI
0 · Reply
Gainermaxim
Gainermaxim Jul. 1 at 5:09 PM
$VSTM she is coming back!
0 · Reply
Marketismanipulated2
Marketismanipulated2 Jul. 1 at 4:54 PM
$VSTM i bought 70k dollars yesterday at $4.04 and sold it all at $4.17 yesterday trying to capitalize on their crimes, guess I still did, wish i kept it all now.
0 · Reply
Adorno99
Adorno99 Jul. 1 at 4:41 PM
$VSTM safe to dip your toes? Should have bought when it was 4.04 or so
1 · Reply
bluermefox
bluermefox Jul. 1 at 4:15 PM
$VSTM safe to dip our toes?
0 · Reply
PencilNeckGeek
PencilNeckGeek Jul. 1 at 4:04 PM
$VSTM Glad to see it looking better today. Would be nice if the worst is over, but not gonna get my hopes up just yet
0 · Reply
gargoyl
gargoyl Jul. 1 at 1:45 PM
$VSTM about pop , second round innn
0 · Reply
TwongStocks
TwongStocks Jul. 1 at 1:27 PM
$VSTM Q2 ended yesterday. The 10-Q is due 45 days after the end of the quarter. Filing deadline is Aug 14. The upcoming 10-Q should provide a glimpse into the initial commercial launch of AVMAPKI FAKZYNJA co-pack, which was approved on May 8.
1 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:10 PM
$VSTM (+1.7% pre) Avutometinib-defactinib combo shows strong results in LGSOC patients https://ooc.bz/l/69139
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 1 at 10:17 AM
WATCHLIST JUL 01 2025 $VSTM Verastem Oncology Announces Publication Of Updated Results From Phase 1/2 FRAME Study Conducted By The Institute Of Cancer Research, London, And The Royal Marsden NHS Foundation Trust, In Nature Medicine $TOI The Oncology Institute Named Exclusive Oncology Provider For 80K SilverSummit Medicaid Patients In Nevada Starting July 1, 2025 $SIDU Sidus Space Collaborates With VORAGO Technologies To Validate And Integrate Next-Gen Radiation-Hardened MCU Technology Through VORAGO's Alpha Customer Program $GANX Gain Therapeutics Completes Target Enrollment In Phase 1b Clinical Study Evaluating GT-02287 In People With Parkinson's Disease With Or Without GBA1 Mutation $ACIW ACI Worldwide And iNet Expand Partnership To Power Saudi Arabia's Fintech Infrastructure With Postilion Platform
0 · Reply
AUgold
AUgold Jul. 1 at 12:46 AM
$VSTM Ink a deal
0 · Reply
hermitkatt
hermitkatt Jul. 1 at 12:31 AM
$VSTM add more here
0 · Reply
Alpinecactus
Alpinecactus Jun. 30 at 10:51 PM
$VSTM Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer PDF Version FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR and mPFS were 58.3% and 30.8 months, respectively
0 · Reply
Universaal
Universaal Jun. 30 at 9:51 PM
$VSTM these guys have been in the business enough time to show some $$$ not just stupid trails and approvals. End of the day market cares about margins.
0 · Reply
tedsie
tedsie Jun. 30 at 9:01 PM
$VSTM I can't wait to see the results for pancreatic cancer, hopefully they will be great at least very good...I want to see if the stock goes down on those results. I still believe will will have our shinning hour with VSTM, I'm holding and waiting and still believing.
2 · Reply
tedsie
tedsie Jun. 30 at 8:30 PM
$VSTM What does the world want from this company, it's definitely keeping people alive longer with there drugs and the stock is in the toilet. Shorts Longs Middles who cares the drugs work and the stock should reflect that but it doesn't. Why don't big Pharma buy them already. The drugs work...Period.
0 · Reply
UWilDue0
UWilDue0 Jun. 30 at 8:14 PM
$VSTM order at $4, low at $4.01, what a surprise. Wish they would have just let it close the gap before tomorrow. Now it feels like $3.50 or lower is in play.
0 · Reply
AUgold
AUgold Jun. 30 at 8:06 PM
$VSTM Strange movement AH
0 · Reply